Get the Daily Brief
Latest Biotech News
New study maps CAR‑T neurotoxicity — safety pathways identified
Recent research advanced understanding of neurotoxicity associated with CAR‑T cell therapies, mapping hemodynamic and cellular events that precede neuroimmune adverse events. The work synthesizes...
SpatialBench: benchmark exposes agents’ demo‑to‑deployment gap
Authors introduced SpatialBench, a suite of 146 verifiable spatial‑biology analysis problems across five platforms and seven task categories, designed to benchmark AI agents on real laboratory...
Nanovaccines for HCC: engineered particles prime liver tumor immunity
Researchers highlighted nanovaccine platforms engineered to stimulate immune responses against hepatocellular carcinoma (HCC), reporting preclinical data that show enhanced antigen presentation...
Targeted protein degradation... raises cross‑species health and ecological questions
A recent review examined targeted protein degradation technologies and their biological impacts across health and species, outlining therapeutic promise alongside ecological and safety...
FDA approves Yartemlea: first approved therapy for a fatal stem‑cell transplant complication
The FDA granted approval to Omeros’s complement‑system drug Yartemlea to treat a severe, potentially fatal complication following hematopoietic stem cell transplantation. The action, reported by...
CMS unveils voluntary payment model – expands Medicare coverage for GLP‑1 weight‑loss drugs
The Centers for Medicare & Medicaid Services launched a voluntary payment model aimed at expanding Medicare coverage for GLP‑1 class weight‑loss drugs, a move reported as part of the Trump...
J&J drops eczema candidate – $1.25bn acquisition yield slashed
Johnson & Johnson discontinued its experimental eczema drug JNJ‑5939 (NM26) after the candidate failed to meet efficacy standards in a mid‑stage trial, the company disclosed. J&J acquired the...
Biohaven’s ion‑channel drug fails Phase‑2 – depression program stumbles
Biohaven announced that its potassium‑channel modulator failed a Phase‑2 trial in major depressive disorder, marking a second mid‑stage setback for the program. The company said the candidate did...
Study maps CAR‑T neurotoxicity mechanisms – route to safer cell therapies
A new study released this year advanced understanding of neurotoxicity associated with CAR‑T cell therapies, detailing clinical and molecular features that underlie treatment‑related neurological...
Engineered AAVs: vectors that sense the tumor microenvironment and adapt
Researchers unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that dynamically respond to tumor microenvironment cues to improve tumor targeting and reduce...
Nanovaccines for HCC: engineered particles enter immunotherapy pipeline
A study described nanovaccine platforms designed to stimulate immune responses against hepatocellular carcinoma (HCC), reporting preclinical efficacy in models and outlining translational routes...
SpatialBench exposes demo‑to‑deployment gap for AI agents in biology
SpatialBench, a new benchmark suite introduced by software and computational biology researchers, revealed major weaknesses in current agent‑based tools when applied to real spatial biology...
SyBValS launches to validate biological pathway maps and curb errors
A new service, SyBValS (System Biology Validation Service), was introduced to validate computationally inferred biological pathways and flag annotation errors that commonly mislead downstream...
Targeted protein degradation – review flags health and ecological considerations
A comprehensive review evaluated the therapeutic promise of targeted protein degradation (TPD) technologies and described potential health‑ and species‑level impacts of deploying degrading agents...
CMS rolls out voluntary Medicare model: GLP‑1 coverage expanded
CMS launched a voluntary payment model designed to broaden Medicare coverage of GLP‑1 weight‑loss drugs. The agency announced the model as a step to increase beneficiary access and address drug...
FDA approves Yartemlea: First therapy for stem‑cell transplant complication
The FDA approved Omeros’s complement‑system drug Yartemlea to treat a severe, potentially fatal complication of hematopoietic stem cell transplants, marking the first regulatory clearance for this...
J&J axes eczema drug — $1.25B acquisition deal unwinds
Johnson & Johnson halted development of an experimental eczema therapy it acquired for $1.25 billion, citing efficacy shortfalls in internal testing. The decision ends expectations tied to the...
CAR‑T neurotoxicity studied: new mechanisms identified
Recent research released new insights into neurotoxicity associated with CAR‑T cell therapies. The work maps clinical patterns and potential biological pathways underpinning neurological adverse...
CAR‑T vs bispecifics... head‑to‑head in relapsed B‑cell NHL
A new meta‑analysis compared CAR‑T therapies with bispecific antibodies in relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphoma, synthesizing efficacy and safety across published trials....
Antibodies neutralize Marburg — cross‑reactivity with Ravn identified
Researchers discovered a class of potent antibodies that cross‑neutralize the Marburg virus and the related Ravn virus, reporting results in npj Viruses. The antibodies show broad activity against...